Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
Status: Recruiting
Location: See all (11) locations...
Study Type: Observational
SUMMARY
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• Age ≥ 18 years at the time of diagnosis of MPN Ph negative
• Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)
• Obtaining informed consent
Locations
Other Locations
Italy
Azienda Ospedaliera Universitaria Consorziale Policlinico
RECRUITING
Bari
Policlinico Sant'Orsola Malpighi
RECRUITING
Bologna
ASST Spedali Civili di Brescia
RECRUITING
Brescia
Policlinico Vittorio Emanuele
RECRUITING
Catania
Ospedale Universitario Federico II
RECRUITING
Napoli
Policlinico Umberto I, Università La Sapienza
RECRUITING
Roma
Azienda Ospedaliera Universitaria Città della Salute e delle Scienza
RECRUITING
Torino
Ospedale San Luigi di Orbassano - Ospedale Mauriziano
RECRUITING
Torino
Azienda Ospedaliera Universitaria Friuli Centrale
RECRUITING
Udine
Azienda Ospedaliera Universitaria Integrata
RECRUITING
Verona
Ospedale Belcolle
RECRUITING
Viterbo
Contact Information
Primary
Elena Maria Elli
elena.elli@libero.it
0392339859
Backup
Benedetta Valeri
benedettavalerihsg@gmail.com
Time Frame
Start Date: 2022-09-08
Estimated Completion Date: 2026-12
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: University of Milano Bicocca